ERCC1 and neutropenia: From the other hand, altered doxorubicin intake by the SLC22A16 variant (p.Asn104=) together with impaired drugs elimination (CYP2C19 p.Pro227=) and slower DNA damage repair with hematopoiesis disturbances (ERCC1 c.1510C>A) seemed to be the basis of recurrent neutropenia.